omniture
logo
Search
基石药业（苏州）有限公司 CSTONE PHARMACEUTICALS
Media Room

Latest News

rss

CStone and EQRx Enter Global Strategic Partnership for Two Immune Checkpoint Inhibitors: sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1)

* CStone to out-license to EQRx exclusive rights to two late-stage immuno-oncology assets for dev...

2020-10-27 07:23 3622

CStone Announces Completion of $200 million Share Sale to Pfizer

SUZHOU, China, Oct. 12, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) announce...

2020-10-12 08:05 6234

CStone Pharmaceuticals Announces Updated Results from Two Studies of Its Anti-PD-L1 Monoclonal Antibody Sugemalimab (CS1001) At 2020 CSCO Annual Meeting

* CS1001-201 study demonstrated an objective response rate (ORR) of 44.7%, a complete response (C...

2020-09-25 15:28 4395

CStone Announces Preliminary Results from a Bridging Study of Avapritinib in Chinese Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors at the 2020 CSCO Annual Meeting

* Avapritinib has demonstrated strong anti-tumor activity in Chinese patients with PDGFRA D842V m...

2020-09-25 14:53 4503

CStone Receives US FDA IND Clearance for CS1001-201 Study to Evaluate Anti-PD-L1 Monoclonal Antibody Sugemalimab Monotherapy in R/R ENKTL

SUZHOU, China, Aug. 31, 2020 /PRNewswire/ -- CStone Pharmaceuticals (SUZHOU) Co., Ltd. ("CStone", H...

2020-08-31 11:35 3857

CStone Pharmaceuticals Reports Financial Results for the First Half of 2020

SUZHOU, China, Aug. 19, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616), a leadi...

2020-08-19 09:33 4655

CStone submits new drug application for the targeted therapy avapritinib in Taiwan for the treatment of adults with advanced PDGFRA exon 18 mutant gastrointestinal stromal tumor

SUZHOU, China, March 27, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HK...

2020-03-27 14:02 1627

CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib

SUZHOU, China, Jan. 24, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKE...

2020-01-24 14:26 3579

CStone successfully hosted the first U.S. R&D Day in New York

* Among CStone's 15 cancer drug candidates, five candidates are in pivotal late-stage clinical de...

2020-01-24 08:18 3953

CStone successfully hosted the first U.S. R&D Day in New York

* Among CStone's 15 cancer drug candidates, five candidates are in pivotal late-stage clinical de...

2020-01-24 08:03 2620

CStone announces first patient dosed in the Phase III trial of CS1001 in combination with chemotherapy in first-line esophageal squamous cell carcinoma

SUZHOU, China, Jan. 8, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX...

2020-01-08 13:45 3167
12345